| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
interpreting the association between cannabis use and increased risk for schizophrenia. |
2006-01-13 |
2023-08-12 |
Not clear |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
recent longitudinal studies from sweden, the netherlands, new zealand, and israel report that cannabis use during childhood and adolescence doubles the risk of later appearance of psychosis or schizophrenia. |
2006-01-13 |
2023-08-12 |
Not clear |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
thus, an alternative explanation of the association between cannabis use and schizophrenia might be that pathology of the cannabinoid system in schizophrenia patients is associated with both increased rates of cannabis use and increased risk for schizophrenia, without cannabis being a causal factor for schizophrenia. |
2006-01-13 |
2023-08-12 |
Not clear |
| Rachel Miller, Joanne McCormack Caponi, Serge Sevy, Delbert Robinso. The Insight-Adherence-Abstinence triad: an integrated treatment focus for cannabis-using first-episode schizophrenia patients. Bulletin of the Menninger Clinic. vol 69. issue 3. 2006-01-10. PMID:16178711. |
insight-adherence-abstinence focused treatment for first episode of schizophrenia and schizoaffective patients is described using examples from clinical practice with 68 patients, 30 of whom have recent or active cannabis misuse. |
2006-01-10 |
2023-08-12 |
Not clear |
| Suresh Sundram, David Copolov, Brian Dea. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn-Schmiedeberg's archives of pharmacology. vol 371. issue 5. 2006-01-05. PMID:15995876. |
antipsychotic drugs are effective in the treatment of cannabis-induced psychosis, but only clozapine appears effective in the treatment of comorbid schizophrenia and cannabis use. |
2006-01-05 |
2023-08-12 |
rat |
| Suresh Sundram, David Copolov, Brian Dea. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn-Schmiedeberg's archives of pharmacology. vol 371. issue 5. 2006-01-05. PMID:15995876. |
if these results can be extrapolated into humans, then this effect of clozapine on the cb1 receptor may be a mechanism that makes it uniquely effective in schizophrenia and comorbid cannabis use. |
2006-01-05 |
2023-08-12 |
rat |
| Cécile Henquet, Robin Murray, Don Linszen, Jim van O. The environment and schizophrenia: the role of cannabis use. Schizophrenia bulletin. vol 31. issue 3. 2005-12-07. PMID:15976013. |
the environment and schizophrenia: the role of cannabis use. |
2005-12-07 |
2023-08-12 |
Not clear |
| Cécile Henquet, Robin Murray, Don Linszen, Jim van O. The environment and schizophrenia: the role of cannabis use. Schizophrenia bulletin. vol 31. issue 3. 2005-12-07. PMID:15976013. |
cannabis use is associated with poor outcome in existing schizophrenia and may precipitate psychosis in individuals with preexisting liability. |
2005-12-07 |
2023-08-12 |
Not clear |
| W Hal. Cannabis use and psychosis. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203510. |
there is more support for the second hypothesis, in that a large prospective study has shown a linear relationship between the frequency with which cannabis has been used by age 18 and the risks over the subsequent 15 years of a diagnosis of schizophrenia. |
2005-10-31 |
2023-08-12 |
Not clear |
| W Hal. Cannabis use and psychosis. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203510. |
there is stronger evidence that cannabis use can exacerbate the symptoms of schizophrenia. |
2005-10-31 |
2023-08-12 |
Not clear |
| W Hal. Cannabis use and psychosis. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203510. |
mental health services should identify patients with schizophrenia who use alcohol, cannabis and other drugs and advise them to abstain or to greatly reduce their drug use. |
2005-10-31 |
2023-08-12 |
Not clear |
| Alan I Gree. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. The Journal of clinical psychiatry. vol 66 Suppl 6. 2005-10-27. PMID:16107180. |
substances commonly abused in patients with schizophrenia include alcohol, cannabis, and cocaine. |
2005-10-27 |
2023-08-12 |
Not clear |
| Alan I Gree. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. The Journal of clinical psychiatry. vol 66 Suppl 6. 2005-10-27. PMID:16107180. |
conventional antipsychotics have not been overly useful in this patient population, but some atypical antipsychotics have been shown to reduce the use of alcohol, cannabis, cocaine, and tobacco in patients with schizophrenia. |
2005-10-27 |
2023-08-12 |
Not clear |
| E A Carlini, José Carlos Galduróz, Ana Regina Noto, Solange A Napp. [A comment on the editorial Cannabis use in adolescence and risk of schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 26. issue 2. 2005-08-25. PMID:15517070. |
[a comment on the editorial cannabis use in adolescence and risk of schizophrenia]. |
2005-08-25 |
2023-08-12 |
Not clear |
| David M Semple, Andrew M McIntosh, Stephen M Lawri. Cannabis as a risk factor for psychosis: systematic review. Journal of psychopharmacology (Oxford, England). vol 19. issue 2. 2005-07-12. PMID:15871146. |
studies selected for meta-analysis included: (i) case-control studies where exposure to cannabis preceded the onset of schizophrenia or schizophrenia-like psychosis and (ii) cohort studies of healthy individuals recruited before the median age of illness onset, with cannabis exposure determined prospectively and blind to eventual diagnosis. |
2005-07-12 |
2023-08-12 |
Not clear |
| David M Semple, Andrew M McIntosh, Stephen M Lawri. Cannabis as a risk factor for psychosis: systematic review. Journal of psychopharmacology (Oxford, England). vol 19. issue 2. 2005-07-12. PMID:15871146. |
for psychotic symptoms, a dose-related effect of cannabis use was seen, with vulnerable groups including individuals who used cannabis during adolescence, those who had previously experienced psychotic symptoms, and those at high genetic risk of developing schizophrenia. |
2005-07-12 |
2023-08-12 |
Not clear |
| Avshalom Caspi, Terrie E Moffitt, Mary Cannon, Joseph McClay, Robin Murray, HonaLee Harrington, Alan Taylor, Louise Arseneault, Ben Williams, Antony Braithwaite, Richie Poulton, Ian W Crai. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological psychiatry. vol 57. issue 10. 2005-06-08. PMID:15866551. |
recent evidence documents that cannabis use by young people is a modest statistical risk factor for psychotic symptoms in adulthood, such as hallucinations and delusions, as well as clinically significant schizophrenia. |
2005-06-08 |
2023-08-12 |
Not clear |
| Yukitaka Morita, Hiroshi Ujike, Yuji Tanaka, Naohiko Uchida, Akira Nomura, Kyohei Ohtani, Makiko Kishimoto, Akiko Morio, Takaki Imamura, Ayumu Sakai, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kurod. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neuroscience letters. vol 376. issue 3. 2005-05-26. PMID:15721218. |
acute and chronic cannabis use can produce drug-induced psychosis resembling schizophrenia and worsen positive symptoms of schizophrenia. |
2005-05-26 |
2023-08-12 |
human |
| Hiroshi Ujike, Yukitaka Morit. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. Journal of pharmacological sciences. vol 96. issue 4. 2005-04-28. PMID:15613777. |
new perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. |
2005-04-28 |
2023-08-12 |
Not clear |
| Hiroshi Ujike, Yukitaka Morit. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. Journal of pharmacological sciences. vol 96. issue 4. 2005-04-28. PMID:15613777. |
cannabis consumption may induce psychotic states in normal individuals, worsen psychotic symptoms of schizophrenic patients, and may facilitate precipitation of schizophrenia in vulnerable individuals. |
2005-04-28 |
2023-08-12 |
Not clear |